Sales of Sanofi's rare-disease treatment Kynamro, approved last January, got off to a slow start, but that situation shouldn't persist now that the French drugmaker's Genzyme unit has beefed up its sales force.
written on 05.03.2014
Sales of Sanofi's rare-disease treatment Kynamro, approved last January, got off to a slow start, but that situation shouldn't persist now that the French drugmaker's Genzyme unit has beefed up its sales force.
See our Cookie Privacy Policy Here